Events

2025 EU MITRE ATT&CK® Community Workshop
MAY
Thu
15
09:30 - 17:00

This was 4 months ago

Location

Hybrid - Brussels and online

Programmes
Security Cybersecurity Defence EDF

Hosted by Eurocontrol and supported by the MITRE Center for Threat-Informed Defense and the Centre for Cybersecurity Belgium (CCB), this full-day hybrid event is built by practitioners, for practitioners. Topics covered include detection engineering, red teaming, or national cyber defense.

The agenda features expert talks on:

  • Applying ATT&CK for resilience and critical infrastructure
  • AI-driven red teaming and detection
  • Cyber insurance and risk-based threat modeling
  • Insights directly from MITRE, CIS, CERT-UA, EC, and more

More information and the possibility to register can be found on the event website.

 

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.